Atherosclerosis
Volume 215, Issue 1 , Pages 34-42 , March 2011

In vivo knockdown of nicotinic acetylcholine receptor α1 diminishes aortic atherosclerosis

  • Guoqiang Zhang

      Affiliations

    • Division of Nephrology, Seattle Children's Hospital, Department of Pediatrics, University of Washington, Seattle, WA 98105, USA
    • Corresponding Author InformationCorresponding author at: C9S, 1900 9th Ave., Seattle, WA, USA. Tel.: +1 206 884 7431; fax: +1 206 884 1407/7175.
    • ,
  • Amanda L. Marshall

      Affiliations

    • Division of Nephrology, Seattle Children's Hospital, Department of Pediatrics, University of Washington, Seattle, WA 98105, USA
    • ,
  • Alison L. Thomas

      Affiliations

    • Division of Nephrology, Seattle Children's Hospital, Department of Pediatrics, University of Washington, Seattle, WA 98105, USA
    • ,
  • Kelly A. Kernan

      Affiliations

    • Division of Nephrology, Seattle Children's Hospital, Department of Pediatrics, University of Washington, Seattle, WA 98105, USA
    • ,
  • Yanyuan Su

      Affiliations

    • Division of Nephrology, Seattle Children's Hospital, Department of Pediatrics, University of Washington, Seattle, WA 98105, USA
    • ,
  • Renee C. LeBoeuf

      Affiliations

    • Division of Endocrine and Metabolic Diseases, Department of Medicine, University of Washington, Seattle, WA 98105, USA
    • ,
  • Xiu Rong Dong

      Affiliations

    • Division of Nephrology, Seattle Children's Hospital, Department of Pediatrics, University of Washington, Seattle, WA 98105, USA
    • ,
  • B.N. Angela Tchao

      Affiliations

    • Division of Nephrology, Seattle Children's Hospital, Department of Pediatrics, University of Washington, Seattle, WA 98105, USA

Received 11 May 2010 ,Revised 10 July 2010 ,Accepted 23 July 2010.

References 

  1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med. 2005;352:1685–1695
  2. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation. 2006;113:898–918
  3. Assmann A, Mohlig M, Osterhoff M, Pfeiffer AFH, Spranger J. Fatty acids differentially modify the expression of urokinase type plasminogen activator receptor in monocytes. Biochem Bioph Res Commun. 2008;376:196–199
  4. Andersson J, Libby P, Hannson GK. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134:33–46
  5. Cooke JP. Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor. Life Sci. 2007;80:2347–2351
  6. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med. 2001;7:833–839
  7. Kanda Y, Watanabe Y. Nicotine-induced vascular endothelial growth factor release via the EGFR-ERK pathway in rat vascular smooth muscle cells. Life Sci. 2007;80:1409–1414
  8. Zhang G, Kernan KA, Thomas A, et al. A novel signaling pathway: fibroblast nicotinic receptor α1 binds urokinase and promotes renal fibrosis. J Biol Chem. 2009;284:29050–29064
  9. Carlisle DL, Liu X, Hopkins TM, et al. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm Pharmacol Ther. 2007;20:629–641
  10. Cooke JP, Ghebremariam YT. Endothelial nicotinic acetylcholine receptors and angiogenesis. Trends Cardiovasc Med. 2008;18:247–253
  11. Rychahou PG, Evers BM. Hydrodynamic delivery protocols. Methods Mol Biol. 2010;623:189–195
  12. Zhang G, Kim H, Xiaohe C, et al. Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy. J Am Soc Nephrol. 2003;14:1234–1253
  13. Zhang G, Kim H, Xiaohe C, et al. Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2003;14:1254–1271
  14. Zhang G, Kernan KA, Collins SJ, et al. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol. 2007;18:846–859
  15. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-β. J Clin Invest. 2009;119:1583–1594
  16. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133–140
  17. Chiba S, Pkamoto H, Kon S, et al. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels. 2002;16:111–117
  18. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultures fibroblasts. J Cell Biol. 1993;122:103–111
  19. Dooley S, Said HM, Gressner AM, et al. Y-box protein-1 is the crucial mediator of antifibrotic interferon-γ effects. J Biol Chem. 2006;281:1784–1795
  20. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 1995;267:1034–1037
  21. Takahashi F, Akutagawa S, Fukumoto H, et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer. 2002;98:707–712
  22. Bobik A, Agrotic A, Kanellakis P, et al. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. Circulation. 1999;99:2883–2891
  23. Lutgens E, Daemen MJ. Transforming growth factor-beta: a local or systemic mediator of plaque stability. Circ Res. 2001;89:853–855
  24. Mallet Z, Gojova A, Marchiol-Fournigault C, et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induced an unstable plaque phenotype in mice. Circ Res. 2001;89:930–934
  25. Otsuka G, Agah R, Frutkin AD, Wight TN, Dichek DA. Transforming growth factor beta-1 induced neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler Thromb Vasc Biol. 2006;26:737–743
  26. McLaren JE, Ramji DP. Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev. 2009;20:125–135
  27. Niwa T, Wada H, Ohashi H, et al. Interferon-gamma produced by bone marrow-derived cells attenuates atherosclerotic lesion formation in LDLR-deficient mice. J Atheroscler Thromb. 2004;11:79–87
  28. Hansson GK, Hellstraand M, Rymo L, Rubbia L, Gabbiani G. Interferon-γ inhibits smooth muscle cell proliferation and expression of differentiation-specific α-smooth muscle actin in arterial smooth muscle cells. J Exp Med. 1989;170:1595–1608
  29. Liu J, Shue E, Ewalt KL, Schimmel P. A new gamma-interferon-inducible promoter and splice variants of an anti-angiogenic human tRNA synthetase. Nucleic Acids Res. 2004;32:719–727
  30. Wakasugi K, Slike BM, Hood J, et al. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc Natl Acad Sci USA. 2002;99:173–177

PII: S0021-9150(10)00602-7

doi: 10.1016/j.atherosclerosis.2010.07.057

Atherosclerosis
Volume 215, Issue 1 , Pages 34-42 , March 2011

Article Tools

* Image Usage & Resolution